Method of treating a motor neuron disease
The mEphA4-Fc dosing regimen with extended intervals addresses the limitations of frequent administration in ALS treatment, enhancing compliance and efficacy by maintaining therapeutic levels, thus slowing disease progression.
WO2026112688A1PCT designated stage Publication Date: 2026-06-04NUNERVE PTY LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- NUNERVE PTY LTD
- Filing Date
- 2025-11-25
- Publication Date
- 2026-06-04
Smart Images
Figure IMGF000036_0001 
Figure IMGF000038_0001 
Figure IMGF000043_0001
Abstract
Disclosed herein are methods for treating a motor neuron disease such as amyotrophic lateral sclerosis (ALS) comprising administering mEphA4-Fc with an interval of greater than every week, for example administering mEphA4-Fc every two weeks, every three weeks, or every four weeks, and at a concentration of about 10 to about 40 mg / kg body weight of a subject.
Need to check novelty before this filing date? Find Prior Art